Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoActive in the last 2 years

Andrew Scott Paulson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-6023-670X; OpenAlex author ID A5001138833, A5017504528. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 2 papers · 2026: 2 papers

Papers 6

  1. NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI … Co-author DOI 10.1016/j.esmoop.2025.106043↗
  2. Response to Letter to the Editor: 'NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgr… Co-author DOI 10.1016/j.esmoop.2026.108307↗
  3. Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic… Co-author DOI 10.1016/j.esmoop.2025.105534↗
  4. A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3). Co-author DOI 10.1080/14796694.2025.2458458↗
  5. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-lab… Co-author DOI 10.1016/s0140-6736(23)01366-1↗
  6. Therapeutic advances in pancreatic cancer. Co-author DOI 10.1053/j.gastro.2013.01.078↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zev A. Wainberg · 5 shared papers, 2023–2026 · strength 0.99
  2. Eileen Mary O'Reilly · 5 shared papers, 2023–2026 · strength 0.99
  3. Roberto Pazo-Cid · 5 shared papers, 2023–2026 · strength 0.99
  4. Davide Melisi · 5 shared papers, 2023–2026 · strength 0.99
  5. Tanios Bekaii‐Saab · 5 shared papers, 2023–2026 · strength 0.99
  6. Richard A Hubner · 5 shared papers, 2023–2026 · strength 0.99
  7. Shubham Pant · 5 shared papers, 2023–2026 · strength 0.99
  8. Eric Van Cutsem · 5 shared papers, 2023–2026 · strength 0.99
  9. Teresa Mercade Macarulla · 5 shared papers, 2023–2026 · strength 0.99
  10. Sreenivasa Rao Chandana · 3 shared papers, 2023–2025 · strength 0.54
  11. Thorsten Oliver Goetze · 3 shared papers, 2023–2025 · strength 0.54
  12. Christelle de la Fouchardière · 3 shared papers, 2023–2025 · strength 0.54
  13. Igor Kišš · 3 shared papers, 2023–2025 · strength 0.54
  14. Hassan A. Hatoum · 2 shared papers, 2026 · strength 0.46
  15. Vincent M. Chung · 2 shared papers, 2026 · strength 0.46
  16. Andrew Peter Dean · 2 shared papers, 2023–2025 · strength 0.34
  17. Woo Jin Lee · 1 shared paper, 2023 · strength 0.14
  18. Hop S. Tran Cao · 1 shared paper, 2013 · strength 0.05
  19. Andrew M. Lowy · 1 shared paper, 2013 · strength 0.05
  20. Margaret A. Tempero · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.